← back to search

Dina Schneider

Lentigen Technology (United States) · US
🔎 Find collaborators in Oncology · Molecular Biology · cancer →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Oncology · Molecular Biology · cancer
Research interest
Research interests include CAR-T cell therapy research, Viral Infectious Diseases and Gene Expression in Insects, Biosimilars and Bioanalytical Methods, and Virus-based gene therapy research.
h-index
25
citations
3,269
works
118
NIH funding
primary concept
Medicine
email

Recent publications

BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial
Nature Medicine 2026cited by 5position: middledoi
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.
Blood cancer discovery 2026cited by 0position: contributordoi
Human CART22.19 Therapy in Refractory Pediatric B-ALL: Insights from a Named-Patient Cohort
medRxiv 2025cited by 0position: middledoi
Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma
Cell Reports Medicine 2023cited by 25position: middledoi
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia
Blood Cancer Journal 2022cited by 110position: middledoi
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients
Nature Communications 2021cited by 73position: middledoi
Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model
Science Translational Medicine 2019cited by 160position: middledoi
A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy
Frontiers in Immunology 2019cited by 86position: middledoi
A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia
Frontiers in Oncology 2018cited by 46position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Rimas J. Orentas · Lentigen Technology (United States)4 papers (2018–2025)Boro Dropulić · Quality Biological3 papers (2018–2019)Dimiter S. Dimitrov · University of Pittsburgh2 papers (2018–2019)Zhongyu Zhu · Henan Provincial People's Hospital2 papers (2018–2019)Winfried Krueger · Lentigen Technology (United States)2 papers (2019–2019)Peirong Hu · Indiana University School of Medicine2 papers (2018–2025)Weizao Chen · Center for Cancer Research2 papers (2018–2019) · 2 papers (2019–2022) · 1 papers (2019–2019) · 1 papers (2019–2019)Congcong Zhang · Miltenyi Biotec (Germany)1 papers (2022–2022)Patrick Schlegel · University of Regensburg1 papers (2025–2025)Mengyan Li · Xinjiang Medical University1 papers (2019–2019)Michael W.M. Kühn · Frankfurt Cancer Institute1 papers (2022–2022)Andrew Worden · GenVec1 papers (2019–2019) · 1 papers (2025–2025) · 1 papers (2019–2019)Els Verhoeyen · Université Claude Bernard Lyon 11 papers (2019–2019)Markus Granzin · Lentigen Technology (United States)1 papers (2019–2019) · 1 papers (2022–2022)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Oncology · Molecular Biology · cancer →